242 related articles for article (PubMed ID: 18998755)
1. Pramlintide in the treatment of diabetes mellitus.
Edelman S; Maier H; Wilhelm K
BioDrugs; 2008; 22(6):375-86. PubMed ID: 18998755
[TBL] [Abstract][Full Text] [Related]
2. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
Ryan GJ; Jobe LJ; Martin R
Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
[TBL] [Abstract][Full Text] [Related]
3. Pramlintide: A new tool in diabetes management.
Want LL; Ratner RE
Curr Diab Rep; 2006 Nov; 6(5):344-9. PubMed ID: 17076994
[TBL] [Abstract][Full Text] [Related]
4. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
Singh-Franco D; Robles G; Gazze D
Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
[TBL] [Abstract][Full Text] [Related]
5. Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control.
Weyer C; Maggs DG; Young AA; Kolterman OG
Curr Pharm Des; 2001 Sep; 7(14):1353-73. PubMed ID: 11472273
[TBL] [Abstract][Full Text] [Related]
6. Pramlintide in the management of insulin-using patients with type 2 and type 1 diabetes.
Pullman J; Darsow T; Frias JP
Vasc Health Risk Manag; 2006; 2(3):203-12. PubMed ID: 17326327
[TBL] [Abstract][Full Text] [Related]
7. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
[TBL] [Abstract][Full Text] [Related]
8. Pramlintide for the treatment of diabetes mellitus.
Kleppinger EL; Vivian EM
Ann Pharmacother; 2003; 37(7-8):1082-9. PubMed ID: 12841822
[TBL] [Abstract][Full Text] [Related]
9. Pramlintide in the treatment of diabetes.
Edelman SV; Darsow T; Frias JP
Int J Clin Pract; 2006 Dec; 60(12):1647-53. PubMed ID: 17109671
[TBL] [Abstract][Full Text] [Related]
10. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
[TBL] [Abstract][Full Text] [Related]
11. The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus.
Fineman M; Weyer C; Maggs DG; Strobel S; Kolterman OG
Horm Metab Res; 2002 Sep; 34(9):504-8. PubMed ID: 12384827
[TBL] [Abstract][Full Text] [Related]
12. Pramlintide acetate.
McQueen J
Am J Health Syst Pharm; 2005 Nov; 62(22):2363-72. PubMed ID: 16278328
[TBL] [Abstract][Full Text] [Related]
13. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
Nyholm B; Orskov L; Hove KY; Gravholt CH; Møller N; Alberti KG; Moyses C; Kolterman O; Schmitz O
Metabolism; 1999 Jul; 48(7):935-41. PubMed ID: 10421239
[TBL] [Abstract][Full Text] [Related]
14. Use of pramlintide: the patient's perspective.
Want L
Diabetes Educ; 2006; 32 Suppl 3():111S-118S. PubMed ID: 16751352
[TBL] [Abstract][Full Text] [Related]
15. Amylin and glycaemic regulation: a possible role for the human amylin analogue pramlintide.
Kolterman OG
Diabet Med; 1997 Jun; 14 Suppl 2():S35-8. PubMed ID: 9212328
[TBL] [Abstract][Full Text] [Related]
16. Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone.
Edelman SV; Weyer C
Diabetes Technol Ther; 2002; 4(2):175-89. PubMed ID: 12079621
[TBL] [Abstract][Full Text] [Related]
17. Optimizing diabetes treatment using an amylin analogue.
Edelman SV
Diabetes Educ; 2008; 34 Suppl 1():4S-10S. PubMed ID: 18268000
[TBL] [Abstract][Full Text] [Related]
18. Clinical implications of amylin and amylin deficiency.
Kruger DF; Gatcomb PM; Owen SK
Diabetes Educ; 1999; 25(3):389-97; quiz 398. PubMed ID: 10531859
[TBL] [Abstract][Full Text] [Related]
19. Amylin receptor agonists: a novel pharmacological approach in the management of insulin-treated diabetes mellitus.
Nyholm B; Brock B; Ørskov L; Schmitz O
Expert Opin Investig Drugs; 2001 Sep; 10(9):1641-52. PubMed ID: 11772274
[TBL] [Abstract][Full Text] [Related]
20. Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk.
Hoogwerf BJ; Doshi KB; Diab D
Vasc Health Risk Manag; 2008; 4(2):355-62. PubMed ID: 18561511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
